Gastroesophageal Cancer
Gastroesophageal Cancer
Advertisement
Katy MarshallGastroesophageal Cancer | April 22, 2024
The prognostic value of the Edmonton Symptom Assessment Scale in patients with gastroesophageal cancer was investigated.
Read More
Katy MarshallGastric Cancer | April 19, 2024
For those with a PD-L1 CPS of 5 or higher who received the combination therapy, the median OS was not achieved.
Emily MenendezGastroesophageal Cancer | April 2, 2024
Chromoendoscopic screening can help reduce esophageal cancer incidence and mortality rates.
Katy MarshallGastroesophageal Cancer | March 27, 2024
The trial’s primary endpoint was safety and the secondary endpoint was feasibility.
Emily MenendezGastroesophageal Cancer | March 15, 2024
Tislelizumab correlated with a higher objective response rate and a better durable antitumor response versus chemotherapy.
Katy MarshallGastroesophageal Cancer | March 14, 2024
Research has shown that trifluridine-tipiracil may increase survival benefit for patients with metastatic EGA.
Yelena Janjigian, MDGastroesophageal Cancer | April 19, 2024
Dr. Janjigian discusses how the agent - created with invariant natural killer t-cells - works in tandem with other therapies.
Yelena Janjigian, MDGastric Cancer | April 19, 2024
Dr. Janjigian describes the history behind nivolumab treatment, and the differences in initial results versus follow-up.
Katy MarshallGastroesophageal Cancer | March 1, 2024
Patients received 2 cycles of sintilimab, paclitaxel, and carboplatin once every 21 days.
Zachary BessetteGastroesophageal Cancer | February 21, 2024
Results of the PANDA study show that atezo has an additive effect with chemo in eliciting tumor response in early G/GEJ.
Katy MarshallGastroesophageal Cancer | February 9, 2024
The study investigated if avelumab and paclitaxel plus ramucirumab would constitute an effective second-line treatment.
Emily MenendezASCO GI 2024 | January 23, 2024
The ESCORT-NEO study explored the use of neoadjuvant camrelizumab with chemotherapy followed by adjuvant camrelizumab.
Katy MarshallASCO GI 2024 | January 23, 2024
Twice-weekly docetaxel plus 5-FU has previously exhibited encouraging antitumor activity.
Zachary BessetteASCO GI 2024 | January 23, 2024
Manish A. Shah, MD, and colleagues are reporting 5-year follow-up data from the randomized, phase 3 KEYNOTE-590 study.
Katy MarshallGastric Cancer | January 23, 2024
The benefits of combination neoadjuvant and adjuvant chemotherapy and immune checkpoint inhibition are currently unknown.
Emily MenendezGastroesophageal Cancer | December 19, 2023
Esophageal cancer is the sixth leading cause of cancer-related deaths and the eighth most common form of cancer worldwide.
Zachary BessetteGastroesophageal Cancer | December 5, 2023
Findings from the EDGE-Gastric trial suggest potential for 2 novel agents in patients with gastroesophageal adenocarcinoma.
Katy MarshallGastroesophageal Cancer | November 2, 2023
The anastomotic leakage rate in the SGC group appeared significantly lower than in the NGC cohort.
Cailin ConnerGastroesophageal Cancer | August 28, 2023
An analysis found that esophageal cancer rates have declined in the United States since 2004.
Rebecca AraujoGastroesophageal Cancer | August 22, 2023
Preoperative induction chemotherapy followed by chemoradiotherapy prior to esophagectomy does not improve survival.
Advertisement
Advertisement
Advertisement
Latest News

April 24, 2024